Lifeward Secures International Distribution Agreement for ReWalk Exoskeleton with Verita Neuro

Reuters12-17 21:01
Lifeward Secures International Distribution Agreement for ReWalk Exoskeleton with Verita Neuro

Lifeward Ltd. announced the expansion of patient access to its ReWalk Personal Exoskeleton through a new international distribution agreement with Verita Neuro, a company under Verita Healthcare Ltd. Under the agreement, Verita Neuro will serve as the exclusive distributor of the ReWalk exoskeleton in Mexico, Thailand, and the United Arab Emirates. The partnership is intended to integrate the ReWalk exoskeleton into Verita Neuro's treatment modalities for people with neurological and spinal cord injuries, providing in-patient training and rehabilitation to support clinical adoption in physical rehabilitation settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9603652) on December 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment